• Oxurion NV announces first patient dosed in its Phase 2 Study evaluating THR-687 for the treatment of Diabetic Macular Edema (DME)

    Wednesday October 13th 2021

  • Precirix dosed first patients in Phase I/II clinical study evaluating CAM-H2 in HER2-positive metastatic cancer

    Wednesday October 6th 2021

  • Galapagos announces completion of patient enrollment for DIVERSITY Phase 3 study with filgotinib in Crohn’s Disease

    Monday October 4th 2021

  • Sequana Medical announces FDA approval to expand patient enrolment in North American pivotal alfapump® study (POSEIDON)

    Monday October 4th 2021

  • OXURION announces positive results from Part A of Phase 2 Study evaluating THR-149 for treatment of Diabetic Macular Edema (DME)

    Thursday September 30th 2021

  • Mithra announces topline results for COVID-19 Phase II Study

    Friday September 24th 2021

  • Donesta® Phase III: recruitment completion of American study and additional recruitment in the European study

    Wednesday September 22nd 2021

  • Precirix and IFE sign clinical trial manufacturing agreement

    Monday September 13th 2021

  • Your news here?

  • ExeVir announces first patient enrolled in phase 1b/2 clinical study evaluating XVR011 as antiviral treatment of patients hospitalised for COVID-19

    Wednesday September 1st 2021

  • Bone Therapeutics announces topline results from Phase III knee osteoarthritis study with its enhanced viscosupplement JTA-004

    Monday August 30th 2021

  • Bone Therapeutics agrees final settlement with the FSMA regarding clinical studies communication issues in 2016 and 2017

    Wednesday July 28th 2021


Strategic Partners